$AZN pushing higher highs
Following favorable safety and tolerability outcomes in early-stage trials, AstraZeneca has advanced AZD5004 into Phase 2 clinical trials.
The study aims to assess weight reduction efficacy in obese and overweight participants, with completion anticipated by late 2025